CrisprBits develops intelligent molecular platforms powered by CRISPR technology for applications across healthcare, food safety, and sustainability. The company offers scalable solutions including PathCrisp for rapid diagnostics, EdiCrisp for precision genome engineering, and CurieCrisp for preclinical disease modeling. These platforms aim to deliver cost-effective innovations in diagnostics, gene editing, and strain engineering sectors.
Funding
$300K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic and therapeutic solutions for infectious diseases, inherited diseases, and cancer can be expensive and inaccessible, particularly in developing countries. Traditional methods may also lack the precision and adaptability to address the diverse range of genetic and infectious disease challenges.
Solution
CrisprBits leverages CRISPR gene-editing technology to create affordable and high-quality diagnostics and therapeutics. The company develops diagnostic tests for infectious diseases, inherited diseases, and cancer, as well as tools for predicting genetic predispositions. CrisprBits also engineers next-generation CAR-T cells and disease tissue models using edited induced pluripotent stem cells (iPSCs) for gene editing and splicing applications. Furthermore, the company is expanding its CRISPR applications to the food and fermentation industries to enhance disease resistance, drought tolerance, yield, and nutritional value in crops, addressing climate change challenges.
Target Audience
The primary target audience includes healthcare providers and patients seeking affordable and advanced diagnostic and therapeutic solutions for infectious and inherited diseases, as well as agricultural companies aiming to improve crop yields and resilience.
Features
- CRISPR-based diagnostics for rapid and accurate detection of infectious diseases, inherited diseases, and cancer
- Ex-vivo gene editing capabilities for creating advanced CAR-T cell therapies and iPSC-derived disease models
- Development of gene splicing techniques for targeted therapeutic interventions
- Application of CRISPR technology to enhance disease resistance and drought tolerance in crops
- Genetic engineering to improve crop yield, reduce spoilage, and enhance nutritional content